EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study

Sarbajit Mukherjee, Yu Fujiwara iD, Christos Fountzilas iD, Harsha Pattnaik, Sarah Chatley, Deepak Vadehra, Moshim Kukar, Kristopher Attwood, Anthony George, Shailesh Advani iD, Han Yu, Kayla Catalfamo und 7 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70835 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2025. Verfasst von Sarbajit Mukherjee und 18 weiteren Autor:innen. Beteiligte Einrichtung: Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Esophagogastric Junction. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Comprehensive Cancer Network Oncology Research Program, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preoperative chemoradiation (CRT) followed by surgery for localized esophageal and gastroesophageal junction adenocarcinoma (EGAC) is a standard of care with a pathologic complete response (pCR) rate of 20%. We evaluated a novel combination of trifluridine/tipiracil with oxaliplatin as induction chemotherapy (IC) followed by CRT.

Methods

We enrolled patients with potentially resectable localized EGAC (T3, T4aN0, or node‐positive disease) in this open‐label, single‐arm, multicenter, Phase II trial between January 2020 and October 2022. Patients received three cycles of IC with trifluridine/tipiracil and oxaliplatin and then underwent concurrent CRT with weekly carboplatin and paclitaxel followed by surgery. The primary objective was to evaluate the pCR rate. The secondary objectives were to evaluate 2‐year progression‐free survival (PFS), 2‐year overall survival (OS), and toxicities. Circulating tumor DNA (ctDNA) was measured at prespecified intervals to assess its correlation with clinical outcomes.

Results

Of the 22 enrolled patients, 19 (86.4%) were male and 20 (90.9%) were Caucasian. The median age was 61 years, and 12 (54.5%) had their primary disease at the gastroesophageal junction. Twenty (90.9%) patients had T3 disease, and 15 (68.2%) had node‐positive disease. Only two patients had pCRs, and an additional five had near pCRs. Since we could not meet our predefined pCR rate at the interim analysis, the study was closed. After a median follow‐up of 15.8 months, 2‐year OS and PFS were 43% and 41%, respectively. ctDNA clearance was associated with a significantly higher OS rate ( p = 0.012) and PFS rate ( p = 0.008). Nausea (59.1%) and fatigue (59.1%) were common treatment‐related adverse events (AEs); nine (40.9%) patients had Grade 3 or higher AEs.

Conclusion

IC with trifluridine/tipiracil and oxaliplatin followed by CRT did not improve pCR rate in resectable EGAC compared to pCR from previous reports with CRT alone. We found a correlation between ctDNA clearance and improved survival, which merits further investigation. Clinical Trial Information NCT04097028.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophagogastric JunctionInduction ChemotherapyOxaliplatinStomach NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedCirculating Tumor DNADrug CombinationsPyrrolidinesThymineTrifluridine

Stichwörter der Autor:innen

circulating tumor DNAesophageal cancerinduction chemotherapypathologic complete responsetrifluridine/tipiracil

Substanzen

Circulating Tumor DNADrug CombinationsOxaliplatinPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combination

Autor:innen und Institutionen

  • Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, USA.
  • Natera, Inc., Austin, Texas, USA.
  • Stephenson Cancer Center - University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • The University of Chicago Medical Center & Biological Sciences, Chicago, Illinois, USA.

ORCID-Profile: Yu Fujiwara, Christos Fountzilas, Shailesh Advani, Erik Spickard

Förderung

  • NCI NIH HHS
  • National Comprehensive Cancer Network Oncology Research Program
  • National Cancer Institute

Zitieren

APA

Mukherjee, S., Fujiwara, Y., Fountzilas, C., Pattnaik, H., Chatley, S., Vadehra, D., Kukar, M., Attwood, K., George, A., Advani, S., Yu, H., Catalfamo, K., Brown, A., Spickard, E., Fungtammasan, A., George, S., Liao, C. Y., Iyer, R., & Hatoum, H. (2025). Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study. Cancer Medicine. https://doi.org/10.1002/cam4.70835

Vancouver

Mukherjee S, Fujiwara Y, Fountzilas C, Pattnaik H, Chatley S, Vadehra D, et al. Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study. Cancer Medicine. 2025. doi:10.1002/cam4.70835

BibTeX
@article{Mukherjee2025,
  author = {Mukherjee, Sarbajit and Fujiwara, Yu and Fountzilas, Christos and Pattnaik, Harsha and Chatley, Sarah and Vadehra, Deepak and Kukar, Moshim and Attwood, Kristopher and George, Anthony and Advani, Shailesh and Yu, Han and Catalfamo, Kayla and Brown, Alyson and Spickard, Erik and Fungtammasan, Arkarachai and George, Sagila and Liao, Chih-Yi and Iyer, Renuka and Hatoum, Hassan},
  title = {Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70835}
}
Kostenlos starten →